Thierry Gorlia

发表

Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.

Jacoline E. C. Bromberg, Michael Platten, Martin Bendszus, 2016 .

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.

Stefano Iacobelli, Francis Lévi, Antoine Adenis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lomustine and Bevacizumab in Progressive Glioblastoma

Martin Klein, Michael Platten, Martin Bendszus, 2017, The New England journal of medicine.

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

Denis Lacombe, Wolfgang Grisold, M. J. van den Bent, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

Denis Lacombe, Johan M Kros, R. Stupp, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome

Caterina Giannini, Ping-Pin Zheng, Felice Giangaspero, 2007, Journal of neuropathology and experimental neurology.

Histopathologic assessment of hot‐spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors

Christine Haberler, Matthias Preusser, Harald Heinzl, 2006, Cancer.

Cost‐effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme

Maiwenn J Al, Ralph Crott, Carin A Uyl-de Groot, 2008, Cancer.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma

Brigitta G. Baumert, Jaap C. Reijneveld, Andreas von Deimling, 2016, The Lancet. Oncology.

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

Winand N M Dinjens, Jean-Yves Delattre, Denis Lacombe, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Pieter Wesseling, Hendrikus J Dubbink, Winand N M Dinjens, 2010, Clinical Cancer Research.

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.

Pieter Wesseling, Peggy N Atmodimedjo, Hendrikus J Dubbink, 2016, Neuro-oncology.

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Pieter Wesseling, Johan M Kros, M. J. van den Bent, 2011, Clinical Cancer Research.

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Elizabeth Eisenhauer, Denis Lacombe, Michael Weller, 2008, The Lancet. Oncology.